Loading organizations...

§ Private Profile · San Carlos, CA, USA
biotechnology company developing substrate replacement therapies for rare genetic diseases, particularly congenital disorders of glycosylation.
Based in San Carlos, California, Glycomine is a clinical-stage biotechnology company developing targeted substrate replacement therapies for serious rare genetic diseases, specifically focusing on congenital disorders of glycosylation. The firm's lead candidate, GLM101, is a mannose-1-phosphate replacement therapy designed to bypass metabolic deficiencies and restore normal protein glycosylation in patients suffering from PMM2-CDG. Because there are currently no approved disease-modifying treatments for this condition, the organization is advancing its pipeline to address these unmet medical needs. Glycomine recently received FDA investigational new drug clearance for GLM101 and initiated patient enrollment for its global Phase 2b clinical trial. To support ongoing clinical advancement, the enterprise has secured approximately $195 million in total venture financing, highlighted by a $115 million Series C round from investors including Novo Holdings, Sanofi Ventures, Abingworth, and Pappas Capital. The company was founded in 2014.
Glycomine has raised $200.0M across 4 funding rounds.
Glycomine has raised $200.0M in total across 4 funding rounds.
Glycomine has raised $200.0M in total across 4 funding rounds.
Glycomine's investors include CTI Life Sciences Fund, 5AM Ventures, Abingworth, Advent Life Sciences, F-Prime Capital Partners, RiverVest, Sanofi Ventures, Dolby Family Ventures, SV Health Investors, Novo Holdings, Sanderling Ventures.
Glycomine is a clinical-stage biopharmaceutical company developing replacement therapies for rare genetic diseases, particularly congenital disorders of glycosylation (CDG) like PMM2-CDG, a severe condition with no approved treatments.[1][2][3][5] Its lead product, GLM101—a substrate replacement therapy—aims to restore missing biological functions by bypassing metabolic blocks, and is currently enrolling patients in a global Phase 2b clinical trial (POLAR) after FDA IND clearance.[1][5] Founded in 2014 and headquartered in San Carlos, California, Glycomine has raised $80M in funding, with its latest Series B-II round of $35M occurring about four years ago, positioning it for advancement in rare disease therapeutics.[1][4]
The company serves patients with ultra-rare disorders affecting glycosylation pathways, solving the critical problem of absent disease-modifying therapies for conditions impacting protein function and causing multisystem debilitation.[2][3] Growth momentum includes preclinical proof-of-concept in patient-derived cells demonstrating restored glycosylation, six patents (focused on rare diseases and proteins), and active clinical progression amid a patient population exceeding 20 million in the U.S. across 7,000 rare disorders.[1][3][5]
Glycomine was founded in 2014 in San Carlos, California, at MBC BioLabs, emerging from the need to address unmet needs in rare genetic diseases like PMM2-CDG (formerly CDG-Ia), an autosomal recessive disorder with no prior therapeutics.[1][2][4] While specific founders are not detailed in available sources, the company originated with a focus on substrate, enzyme, and protein replacement therapies to restore glycosylation—a key biological process disrupted in these inherited metabolic disorders.[1][2] Early traction came from preclinical studies in patient-derived fibroblasts showing successful bypass of metabolic blocks, leading to FDA clearance for GLM101's IND and initiation of clinical trials.[2][5]
Glycomine rides the wave of precision medicine and gene-agnostic therapies for rare diseases, capitalizing on advances in glycosylation biology and orphan drug incentives that favor small-patient populations.[3][5] Timing is ideal amid growing recognition of 7,000+ rare disorders affecting over 20 million in the U.S., where most lack disease-modifying options, amplified by regulatory fast-tracks like FDA IND clearance.[1][3] Market forces include rising biotech investment in ultra-rares (despite Glycomine's funding pausing ~4 years ago) and trial designs like POLAR enabling global enrollment for conditions with few hundred patients each.[1][5] It influences the ecosystem by pioneering metabolic bypass strategies, potentially setting precedents for similar disorders and attracting partners like Pappas Capital.[2]
Glycomine's path hinges on POLAR trial topline data, which could validate GLM101 and propel it toward Phase 3 or partnerships, unlocking orphan drug exclusivity and premium pricing.[5] Trends like AI-driven rare disease diagnostics and expanded FDA incentives will accelerate its journey, while expansion to adjacent CDG subtypes could broaden impact.[1][3] Its influence may evolve from niche innovator to category leader if GLM101 succeeds, transforming lives in PMM2-CDG and inspiring replication therapies—ultimately delivering the quality-of-life gains promised in its mission for the underserved rare disease space.[3][5]
Glycomine has raised $200.0M across 4 funding rounds. Most recently, it raised $120.0M Series C in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2025 | $120M Series C | CTI Life Sciences Fund | 5AM Ventures, Abingworth, Advent Life Sciences, F Prime Capital, Rivervest, Sanofi Ventures | Announced |
| Jun 1, 2021 | $35M Series B | Abingworth, Sanofi Ventures | 5AM Ventures, Dolby Family Ventures, F Prime Capital, Rivervest, SV Health Investors | Announced |
| Aug 7, 2019 | $33M Series B | Novo Holdings | — | Announced |
| Nov 16, 2016 | $12M Series A | Sanderling Ventures | — | Announced |